Ian Ying Woo - 15 Oct 2026 Form 4 Insider Report for NovaBridge Biosciences (NBP)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
19 Oct 2026, 16:15:10 UTC
Prior SEC filing
18 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kyler Lei, Attorney-in-Fact
Filing notes and source

Key filing fact

Ian Ying Woo filed Form 4 for NovaBridge Biosciences (NBP) on 19 Oct 2026.

Key facts

  • This page summarizes Ian Ying Woo's Form 4 filing for NovaBridge Biosciences (NBP).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 19 Oct 2026, 16:15.

Change

  • Previous filing in this sequence was filed on 18 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002115245 Primary reporting owner

Woo Ian Ying

Relationship
Director
Address
C/O NOVABRIDGE BIOSCIENCES, 2440 RESEARCH BOULEVARD, SUITE 400, ROCKVILLE
Signature
/s/ Kyler Lei, Attorney-in-Fact
Signature date
19 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBP transaction

Ordinary Shares

Options Exercise

Transaction value
Shares
+13,271
Change %
Price
Shares after
13,271
Date
15 Oct 2026
Ownership
Direct
Footnotes
F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBP transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares
-5,770
Change %
-33%
Price
$0.000000*
Shares after
11,540
Date
15 Oct 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
5,770
Exercise price
Footnotes
F1, F3, F4, F5, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

Footnote F2

Reported securities are represented by 5,770 ADSs.

Footnote F3

Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.

Footnote F4

Reported securities represent ADSs.

Footnote F5

On October 15, 2025, the Reporting Person was granted 17,310 restricted share units ("RSUs"). The RSUs vest or shall vest over three years in equal annual installments on October 15, 2026, 2027 and 2028.

Footnote F6

Reported securities represent ADSs.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .